每经头条（nbdtoutiao）——一纸文件征求意见，药店老板们睡不着觉了 （记者 王晓波） 每经AI快讯，信立泰（SZ 002294，收盘价：50.53元）8月19日晚间发布公告称，公司第六届第十三次 董事会会议于2025年8月18日在公司会议室以现场、通讯及书面方式召开。会议审议了《深圳信立泰药 业股份有限公司2025年半年度报告》等文件。 2025年1至6月份，信立泰的营业收入构成为：医药制造业占比91.46%，医疗器械占比8.54%。 截至发稿，信立泰市值为563亿元。 ...

（文章来源：证券日报） 证券日报网讯 8月19日晚间，信立泰发布公告称，公司第六届董事会第十三次会议审议通过了《关于参 与认购股权投资基金份额的议案》等多项议案。 ...

Core Viewpoint - The company, Shenzhen Xinlitai Pharmaceutical Co., Ltd., announced the approval of a special report regarding the use and storage of raised funds for the first half of 2025 by its sixth supervisory board's tenth meeting [2] Group 1 - The company held a supervisory board meeting to review and approve the special report on the use of raised funds [2] - The report pertains to the financial activities and management of funds raised by the company [2]

Core Viewpoint - The company reported a year-on-year increase in both revenue and net profit for the first half of 2025, indicating positive financial performance and growth potential [2] Financial Performance - The company's operating revenue for the first half of 2025 was approximately 2.131 billion yuan, representing a year-on-year increase of 4.32% [2] - The net profit attributable to shareholders was around 365 million yuan, showing a year-on-year increase of 6.1% [2] - Basic earnings per share were reported at 0.33 yuan, which is a year-on-year increase of 6.45% [2]

Group 1 - The core viewpoint of the article highlights that Xinlitai (002294) reported a revenue of 2.131 billion yuan for the first half of 2025, reflecting a year-on-year growth of 4.32% [1] - The net profit attributable to the company for the same period was 365 million yuan, showing a year-on-year increase of 6.1% [1] - The company's research and development investment amounted to 542 million yuan, which represents 25.43% of its revenue [1]

Group 1 - The core point of the article highlights the performance of the Huatai Fuhua Medical Service Flexible Allocation Mixed A Fund, which has shown significant returns over various time frames, including a 69.10% return over the past six months and a 65.45% return year-to-date, ranking first in its category [1] - The fund's latest net value is reported at 1.9920 yuan, reflecting a decrease of 0.75% [1] - The fund's top ten stock holdings account for a total of 68.66%, with notable investments in companies such as Heng Rui Pharmaceutical (9.90%) and Ke Lun Pharmaceutical (9.03%) [1] Group 2 - The Huatai Fuhua Medical Service Flexible Allocation Mixed A Fund was established on June 18, 2015, and as of June 30, 2025, it has a total scale of 2.915 billion yuan [1] - The fund manager, Zhang Wei, has a strong background in biomedical studies and extensive experience in the pharmaceutical sector, having held various positions in research and fund management [2]

Core Viewpoint - The company reported a revenue of 2.131 billion yuan for the first half of 2025, reflecting a year-on-year growth of 4.32% and a net profit attributable to shareholders of 365 million yuan, which is a 6.10% increase compared to the previous year [1] Financial Performance - Revenue for the reporting period was 2.131 billion yuan, up 4.32% year-on-year [1] - Net profit attributable to shareholders reached 365 million yuan, marking a 6.10% increase [1] - Net profit excluding non-recurring gains and losses was 347 million yuan, showing a growth of 3.93% [1] - Basic earnings per share were 0.33 yuan [1] Product Development and Market Position - The company experienced significant growth in sales of patented and new products, which have become a core pillar of its performance [1] - In the hypertension sector, the company has established a differentiated product portfolio, continuously enriching it with products such as Xinlitai (ARB class), Xinchao Tuo (ARNI class), and Fuli Tain (ARB/CCB compound preparation) [1] - The product offerings are designed to precisely meet the medication needs of different patients [1]

格隆汇8月19日丨信立泰(002294.SZ)公布2025年半年度报告，上半年公司实现营业收入21.31亿元，同比 增长4.32%；归属于上市公司股东的净利润3.65亿元，同比增长6.10%；归属于上市公司股东的扣除非经 常性损益的净利润3.47亿元，同比增长3.93%；基本每股收益0.33元。 ...

- 1 - 深圳信立泰药业股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：深圳信立泰药业股份有限公司 单位：人民币万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 司的关联关系 | 上市公司 核算的会计科目 | 2025 年 1-6 月期 初往来资 金余额 | 2025 年 1-6 月 往来累计发生 金额 （不含利息） | 2025 年 1-6 月往 来资金的 利息 | 2025 年 1-6 月偿 还累计 发生金 | 2025 年 1-6 月期 末往来 资金余 | 占用形成 原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | （如有） | 额 | 额 | | | | 控股股东、实际控 | | | | | | | | | | | | 制人及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前控股股东、实际 控制人及其附属企 | | | | | | | | | ...

关于参与认购股权投资基金份额的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、对外投资概述 （一） 基本情况 根据公司战略发展规划，深圳信立泰药业股份有限公司（下称"公司"或"信 立泰"）拟作为有限合伙人，参与认购深圳市松禾资本管理有限公司（下称"松 禾资本"）管理的深圳市松禾细胞与基因产业私募股权投资基金合伙企业（有限 合伙）（下称"松禾细胞"或"合伙企业"）份额。松禾细胞总募集规模不超过 15 亿元，公司拟以自筹资金认缴出资额不超过人民币 5,000 万元。 证券代码：002294 证券简称：信立泰 编号：2025-045 深圳信立泰药业股份有限公司 （二） 董事会审议情况 《关于参与认购股权投资基金份额的议案》，已经公司第六届董事会第十三 次会议以 9 人同意，0 人反对，0 人弃权审议通过。 （三） 投资行为所必需的审批程序 本次投资事项在公司董事会决策权限内，无需提交公司股东大会审议批准。 本次投资事项不构成关联交易，不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。 董事会授权公司管理层负责签署与本次交易相关的对应法律文件，以及 ...